New Tests
Catch Up with New and Enhanced Tests in All Methodologies
Innovation is one of NeoGenomics’ company values. We mean that literally – innovation is one of our Core Values – and we take it personally. We are continually refining and adding new assays in hereditary and somatic molecular genetics, IHC, FISH, flow cytometry, and cytogenetics to keep our test menu at the forefront of cancer diagnostics. To stay up-to-date with our latest news, please sign up for our newsletter here.
Please Review Our List of Recently Launched Tests:
- PD-L1 22C3 FDA (KEYTRUDA®) for TNBC (Breast) (11-20-2020)
- Ki67 NET (10-22-2020)
- PIT1 (9-28-2020)
- Full Focus Cancer Panel (Germline) (9-23-2020)
- DLL3 (9-2-2020)
- NeoTYPE® Follicular Lymphoma Profile (8-4-2020)
- MYC Amplification for Angiosarcoma (7-13-2020)
- PDGFB Rearrangement (22q13) (7-13-2020)
- InVisionFirst®-Lung Liquid Biopsy (6-29-2020)
- NeoLAB® Solid Tumor Liquid Biopsy (6-29-2020)
- PIK3CA Mutation CDx - Plasma (6-25-2020)
- FGFR2 Rearrangement (6-15-2020)
- PRAME (5-25-2020)
- BRG1 (SMARCA4) (5-25-2020)
- PD-L1 28-8 FDA (OPDIVO® + YERVOY®) for NSCLC (5-25-2020)
- H3K27me3 (5-5-2020)
- Ploidy FISH for Molar Pregnancy (5-4-2020)
- Lymphoma Consult (4-20-2020)
- COMPASS® Select Hematopathology Services (4-6-2020)
- COMPASS® Hematopathology Services (4-6-2020)
- JAK2 V617F Mutation Analysis - Quantitative (3-17-2020)
- Rapid AML Therapeutic Panel (3-11-2020)
- JAK2 (9p24.1) (3-5-2020)
- MAP2K1 Mutation Analysis (1-28-2020)
- ERBB2 Mutation Analysis (1-28-2020)
- CTNNB1 Mutation Analysis (1-28-2020)
- 1p36 Deletion (12-20-2019)
- CD103 (12-20-2019)
- CD68 (PG-M1) (12-20-2019)